racemetirosine has been researched along with Adverse Drug Event in 1 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, J | 1 |
| Cord, BJ | 1 |
| McCann, UD | 1 |
| Callahan, BT | 1 |
| Ricaurte, GA | 1 |
1 other study available for racemetirosine and Adverse Drug Event
| Article | Year |
|---|---|
Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity.
Topics: Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Corpus Striatum; Cytoplasm; Cytoplasmic | 2002 |